Technical Analysis for PLRX - Pliant Therapeutics, Inc.

Grade Last Price % Change Price Change
D 31.72 -2.79% -0.91
PLRX closed down 2.79 percent on Thursday, May 6, 2021, on 80 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical PLRX trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Multiple of Ten Bullish Other 0.00%
50 DMA Resistance Bearish -2.79%
Bearish Engulfing Bearish -2.79%
Stochastic Sell Signal Bearish -2.79%
Expansion Pivot Sell Setup Bearish Swing Setup -2.79%
20 DMA Support Bullish -2.79%
Weak + Overbought Other -2.79%
Weak, Overbought and Reversal Signs Reversal -2.79%
Overbought Stochastic Strength -2.79%
Older End-of-Day Signals for PLRX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 1 ATR about 17 hours ago
60 Minute Opening Range Breakdown about 19 hours ago
Down 5% about 19 hours ago
10 DMA Resistance about 20 hours ago
Up 2% about 20 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Pliant Therapeutics, Inc. Description

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that it is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting two Phase 2a trials of PLN-74809 for the treatment of IPF and plans to initiate a Phase 2a trial in PSC in the second half of 2020. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Alcohol Steatohepatitis Hepatitis Hepatology Non Alcoholic Fatty Liver Disease Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Fibrosis Drug Design Orphan Drug Treatment Of Idiopathic Pulmonary Fibrosis Treatment Of Fibrosis Liver Fibrosis Muscular Dystrophies Primary Sclerosing Cholangitis Integrin

Is PLRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 43.92
52 Week Low 19.425
Average Volume 191,091
200-Day Moving Average 28.18
50-Day Moving Average 35.03
20-Day Moving Average 31.55
10-Day Moving Average 32.98
Average True Range 2.54
ADX 16.2
+DI 17.16
-DI 21.43
Chandelier Exit (Long, 3 ATRs ) 30.25
Chandelier Exit (Short, 3 ATRs ) 35.58
Upper Bollinger Band 35.59
Lower Bollinger Band 27.50
Percent B (%b) 0.52
BandWidth 25.66
MACD Line -0.38
MACD Signal Line -0.72
MACD Histogram 0.3364
Fundamentals Value
Market Cap 1.13 Billion
Num Shares 35.5 Million
EPS 0.27
Price-to-Earnings (P/E) Ratio 116.45
Price-to-Sales 10.62
Price-to-Book 3.34
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 36.75
Resistance 3 (R3) 36.74 35.04 35.91
Resistance 2 (R2) 35.04 33.76 35.05 35.63
Resistance 1 (R1) 33.38 32.97 32.53 33.40 35.35
Pivot Point 31.69 31.69 31.26 31.69 31.69
Support 1 (S1) 30.03 30.40 29.18 30.04 28.09
Support 2 (S2) 28.33 29.61 28.34 27.81
Support 3 (S3) 26.67 28.33 27.53
Support 4 (S4) 26.69